Pirfenidone in post-COVID-19 pulmonary fibrosis (FIBRO-COVID): a phase 2 randomised clinical trial

The overall improvements in lung function and HRCT fibrotic score after 6 months with pirfenidone were not significantly different than with placebo.

Authors

Institutions

Publication Details

Journal
European Respiratory Journal
Published
2025-03-28
DOI
https://doi.org/10.1183/13993003.02249-2024
Citations
11
Primary Topic
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Type
article
Field-Weighted Citation Impact
16.70

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Pirfenidone in post-COVID-19 pulmonary fibrosis (FIBRO-COVID): a phase 2 randomised clinical trial

C. Ramírez, Eva Balcells, Guadalupe Bermudo, Santiago Bolívar et al.
11 citations
European Respiratory Journal
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
16.70
article

Pirfenidone in post-COVID-19 pulmonary fibrosis (FIBRO-COVID): a phase 2 randomised clinical trial

C. Ramírez, Eva Balcells, Guadalupe Bermudo, Santiago Bolívar, Ana Montes‐Worboys, Marta Hernández, Yasmina Gutiérrez-Rodríguez, José-Antonio Rodríguez-Portal, Rosalía Laporta, Silvia Barril, Jessica González, Mireya Fuentes, Cristina Caupena, Diego Castillo, Diana Badenes‐Bonet, M. Badia, Vanesa Vicens‐Zygmunt, Jaume Bordas-Martínez, María Molina‐Molina, Claudia Valenzuela, José Sanz‐Santos, Patricio Luburich, Karina Portillo, Paloma Millán-Billi, Salud Santos, Javier Alarcón, Rosana Blavia, Belén del Río, Pilar Hereu, Jacobo Sellarés, Juan Rigual Bobillo, Koral Fernández de Roitegi, Laura Tomás, Judith Peñafiel, Tomás Franquet, Paloma Caballero, Anna Ferrer
article en
11 citations

Abstract

The overall improvements in lung function and HRCT fibrotic score after 6 months with pirfenidone were not significantly different than with placebo.

European Respiratory JournalVol. 65(4)
Universitat Pompeu Fabra (ES), Universidad de Alcalá (ES), Instituto Cajal (ES), Hospital de Sant Pau (ES), Bellvitge University Hospital (ES), Hospital Universitari Arnau de Vilanova (ES), Institut d'Investigació Biomédica de Bellvitge (ES), University Hospital Mútua de Terrassa (ES), Hospital Universitario Puerta de Hierro Majadahonda (ES), Hospital Txagorritxu (ES), Ajuntament de L’Hospitalet (ES), Centre for Biomedical Network Research on Rare Diseases (ES), Hospital Clínic de Barcelona (ES), Instituto Ramón y Cajal de Investigación Sanitaria (ES), Parc Sanitari Sant Joan de Déu (ES), Mútua Terrassa (ES), Hospital Universitario de La Princesa (ES), Hospital de Sant Joan Despí Moisès Broggi (ES), Instituto de Investigación Biomédica de Lleida (ES), Hospital Universitario De Cabueñes (ES), Hospital Universitario Virgen del Rocío (ES), Hospital Universitari Germans Trias i Pujol (ES), Hospital Universitario Ramón y Cajal (ES), Medical Research Network (US), Hospital de Figueres, Universitat de Barcelona (ES)
Roche, Instituto de Salud Carlos III
Openalex Percentile: Top 1%
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
16.70
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.